Post-earnings recap
Reported
Wed, Oct 30, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Cytokinetics reported a larger-than-expected loss per share, which contributed to a 3.11% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's financial health and future prospects. Overall, the results indicate ongoing challenges for the company.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | -377.78% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current financial performance. They did not provide specific guidance for future quarters.
Management did not provide specific insights on revenue expectations.
The company acknowledged challenges in achieving profitability.